Entity

Time filter

Source Type

Princeton, NJ, United States

Davidson M.H.,University of Chicago | Davidson M.H.,Omthera Pharmaceuticals
Current Opinion in Lipidology | Year: 2013

PURPOSE OF REVIEW: Fish oil contains a complex mixture of omega-3 fatty acids, which are predominantly eicosapentaenoic acid (EPA), docosapentaenoic acid, and docosahexaenoic acid (DHA). Each of these omega-3 fatty acids has distinct biological effects that may have variable clinical effects. In addition, plasma levels of omega-3 fatty acids are affected not only by dietary intake, but also by the polymorphisms of coding genes fatty acid desaturase 1-3 for the desaturase enzymes that convert short-chain polyunsaturated fatty acids to long-chain polyunsaturated fatty acids. The clinical significance of this new understanding regarding the complexity of omega-3 fatty acid biology is the purpose of this review. RECENT FINDINGS: FADS polymorphisms that result in either lower levels of long-chain omega-3 fatty acids or higher levels of long-chain omega-6 polyunsaturated fatty acids, such as arachidonic acid, are associated with dyslipidemia and other cardiovascular risk factors. EPA and DHA have differences in their effects on lipoprotein metabolism, in which EPA, with a more potent peroxisome proliferator-activated receptor-alpha effect, decreases hepatic lipogenesis, whereas DHA not only enhances VLDL lipolysis, resulting in greater conversion to LDL, but also increases HDL cholesterol and larger, more buoyant LDL particles. SUMMARY: Overall, these results emphasize that blood concentrations of individual long-chain polyunsaturated fatty acids, which reflect both dietary intake and metabolic influences, may have independent, but also complementary- biological effects and reinforce the need to potentially provide a complex mixture of omega-3 fatty acids to maximize cardiovascular risk reduction. © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins. Source


Patent
Chrysalis Pharma AG and Omthera Pharmaceuticals | Date: 2013-01-04

DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented.


Patent
Omthera Pharmaceuticals and Chrysalis Pharma AG | Date: 2015-04-29

DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented.


Patent
Omthera Pharmaceuticals | Date: 2013-05-07

The present disclosure provides pharmaceutical compositions of statins and polyunsaturated fatty acids (PUFAs), in which the statins are dissolved in the PUFAs, the PUFA species being present substantially in the free acid form. Also provided are oral unit dosage forms of the disclosed pharmaceutical compositions and methods of treating blood lipid disorders using the compositions and oral unit dosage forms.


Methods of identifying subjects who are resistant to antiplatelet therapy, such as therapy with clopidogrel, are presented. The methods comprise determining is whether the subject is an efficient converter of medium chain polyunsaturated fatty acids to long-chain polyunsaturated fatty acids. Also provided are methods of treating resistance to antiplatelet therapy in subjects who are efficient converters of medium chain polyunsaturated fatty acids to long-chain polyunsaturated fatty acids, comprising adjunctively administering to the subject an effective amount of a composition comprising omega-3 long chain polyunsaturated fatty acids. Improved methods of antiplatelet therapy are provided, wherein the improvement comprises adjunctive administration of a composition comprising omega-3 long chain polyunsaturated fatty acids in free acid form. Dosage forms comprising at least one antiplatelet agent and compositions comprising omega-3 long chain polyunsaturated fatty acids, including compositions comprising omega-3 long chain polyunsaturated fatty acids in free acid form, are provided.

Discover hidden collaborations